Leukemia ER, Janka-Schaub GE, Creutzig U, Veerman AJP. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB-types and comparison with acute lymphoblastic leukemia. Blood 2000; 96: 2879-2886. Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML Leukemia (2003) 17, 470-471. doi:10.1038/sj.leu.2402806 TO THE EDITOR A major cause of treatment failure in patients with acute myeloid leukemia (AML) is the occurrence of resistance to structurally and functionally unrelated drugs, called multidrug resistance (MDR). Several mechanisms of drug resistance have been identified; one of these is the overexpression of adenosine triphosphate (ATP)-dependent membrane proteins that function as drug efflux pumps. The best-characterized drug efflux pump is the permeability-glycoprotein (P-gp) which is encoded by the MDR1 gene.
Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML Leukemia (2003) 17, 470-471. doi:10.1038/sj.leu.2402806
TO THE EDITOR
A major cause of treatment failure in patients with acute myeloid leukemia (AML) is the occurrence of resistance to structurally and functionally unrelated drugs, called multidrug resistance (MDR). Several mechanisms of drug resistance have been identified; one of these is the overexpression of adenosine triphosphate (ATP)-dependent membrane proteins that function as drug efflux pumps. The best-characterized drug efflux pump is the permeability-glycoprotein (P-gp) which is encoded by the MDR1 gene. 1 Expression of MDR1 has been identified as an independent adverse prognostic factor for complete remission and survival in adult patients with AML. 1 Recent studies suggested that the results in the treatment of adult patients with AML can be improved by combining chemotherapy with drugs that inhibit the function of P-gp such as cyclosporine.
1,2 However, AML is a rare disease in children and so far, too few data on the clinical relevance of P-gp in childhood AML are available.
The aim of this study was to find out whether the expression of the MDR1 gene indicates a poor prognosis in childhood AML. If that was the case, it would provide evidence in favor of clinical trials with drugs that inhibit the function of P-gp in children with AML.
MDR1 gene expression was measured using TaqMan real time PCR in 58 children with de novo AML. Nine patients were also analyzed in relapse. In 15 patients, in vitro drug resistance was measured by methylthiazoltetrazolium (MTT) assays with cytarabine, daunorubicin, etoposide, vincristine and thioguanine.
The group of patients and the methods of sample collection, sample processing and real time PCR were all identical to our study on the expression of the breast cancer resistance protein (BCRP) which was recently published in this journal. 3 PCR primers and TaqMan probe for MDR1 amplification were used as described by Schiedlmeier et al. 4 The cell line CEM-ADR5000 was used to generate the standard curves. The regression coefficients ranged between 0.995 and 0.998. MTT assays were performed as described by Yamada et al. 5 Measurable amounts of MDR1 were found in all patient samples ( Figure 1 ). The expression levels varied about 20-fold from the 10th percentile to the 90th percentile. Relative to the reference cell line CEM-ADR5000, which was selected because of its high expression of MDR1, the median expression of the patient samples was 0.0015. Three samples of CD34 + stem cells from healthy donors showed levels of MDR1 gene expression that were similar to the highest levels found in AML patients (median 0.011). No significant difference was found between the expression of MDR1 gene in four samples of bone marrow and four samples of peripheral blood from healthy donors. The expression in all of these eight samples was similar to the lowest levels that were found in AML patients (median 0.00047 in blood and 0.00042 in bone marrow).
Forty patients achieved remission and 18 did not. The distribution of MDR1 gene expression in both groups was very similar.
When using the 25th, the 50th or the 75th percentile of MDR1 gene expression as cutoff for high and low expression we found no significant difference in overall survival between the groups. The Kaplan-Maier estimate for overall survival was even higher in patients whose MDR1 gene expression levels were higher than the median as compared to patients with low levels of MDR1 (Figure 2 ). It therefore seems very unlikely that high expression of the MDR1 gene could be found to be an indicator of a significantly worse prognosis in larger studies. The results were similar when relapse-free survival was calculated instead of overall survival.
Sievers et al 6 measured the expression of P-gp in 130 children with de novo AML by flow cytometry. Dahl et al 7 studied the expression of MDR1 (RT-PCR) and P-gp (flow cytometry) in 59 children with relapsed or refractory AML. Both groups found no prognostic implication of P-gp. Those two studies and our results provide supplementing information. Together, they strongly suggest that the expression of the MDR1 gene and its product, P-gp, do not define a poor prognostic group in childhood AML.
MDR1 gene expression was unevenly distributed among the different FAB types (Kruskal-Wallis test P = 0.004) with high levels in M1 and M2 and low levels in M4 and M5. Median expression of MDR1 was four-fold higher in patients with Auer rods than in patients without (Mann-Whitney test P < 0.0001) and also four-fold higher in patients with the translocation t(8;21) than in patients without this translocation (Mann-Whitney test P = 0.002; Figure 1 ). The latter correlation was also described by Pearson et al 8 in a series of 20 pediatric AML samples. We also found an inverse correlation between MDR1 gene expression and initial white blood count (P = 0.003; Spearman's correlation coefficient −0.39).
These findings suggest that the expression of MDR1 is higher in children with favorable subgroups of AML. In our study on the expression of BCRP in childhood AML we found a very similar pattern of expression, 3 but we could also show that high levels of BCRP indicated a poor prognosis when comparing patients with otherwise similar risk factors.
We were not able to demonstrate such an association between MDR1 gene expression and prognosis. However, in larger studies it could possibly be found that MDR1 gene, like BCRP, is expressed at higher levels in favorable subgroups of pediatric AML but indicates a poor prognosis within each subgroup.
In 15 patients we analyzed in vitro drug resistance to cytarabine, adriamycin, etoposide, vincristine and thioguanine by means of MTT assays. Only resistance to vincristine, which is probably the least important of those five drugs in the treatment of childhood AML, was associated with a high expression of MDR1 (Spearman's correlation coefficient 0.62; P = 0.032). Although the absence of a correlation with resistance to the other four drugs might be attributed to the small number of patients, this finding also suggests that MDR1 is not the major cause of drug resistance in childhood AML. Den Boer et al 9 studied the association of P-gp expression with in vitro drug resistance
Figure 2
MDR1 gene expression and overall survival. The median was used as cutoff for high and low expression. The difference between the two groups was not statistically significant. N, number of patients; OS, overall survival; SE, standard error.
in 20 samples from children with AML. No correlation of P-gp with resistance to daunorubicin, vincristine or etoposide was found.
We analyzed nine patients at initial stage as well as in first relapse. A trend for higher levels of MDR1 gene expression at the time of relapse was found but this trend was not statistically significant (Wilcoxon test P = 0.13).
It is difficult to say why the prognostic relevance of P-gp in childhood AML could be different from adult patients. One possible explanation it that most pediatric therapy regimens are more intensive than those which are applied in adult patients. Thus, drug resistance mediated by P-gp could be overcome by the higher dosage and the higher number of co-administered drugs.
The major limitation of this study is that our patients were treated according to four different multi-center studies. 3 However, the expression of MDR1 was evenly distributed among the four studies and to avoid a bias due to the different outcome in the four studies all calculations were repeated, using the number of the study as a stratification variable.
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Internal tandem duplications of FLT3 gene, that represents a strong prognostic factor for overall survival (OS) in AML patients younger than 60 years, seems a rare event in t(8;21) and inv(16)/t(16;16). [1] [2] [3] By contrast, c-kit point mutations are more frequently described in core binding factor (CBF) leukemia; in this setting we previously reported the presence of both D816Y and D816V point mutations in six of 15 patients (40%) [4] [5] [6] and Gari et al 7 found an incidence of the c-kit proto-oncogene deletion plus insertion mutations of 33% among 21 patients with inv(16) and of 5% in patients with t(8;21). However little is known about their prognostic significance.
Recently a retrospective multicenter study on 154 adults and children with t(8;21) AML demonstrated that the WBC index (expressed as WBC × [% marrow blasts/100]) was the only prognostic factor for disease-free survival (DFS), complete remission (CR) duration and OS.
